Carmine Rossi
Education
Ph.D. and M.Sc., epidemiology, McGill University; B.A., human environment, Concordia University
Summary of Experience
Dr. Rossi is an epidemiologist with expertise in biostatistics and clinical research, which he applies to address a range of analytical questions in the field of health economics and outcomes research (HEOR). He has experience designing and implementing real-world data (RWD) analytic and economic modeling solutions for industry clients. His research evaluating and comparing the clinical and economic impacts of novel treatments spans a variety of therapeutic areas, including infectious diseases, mental health, oncology, and hematology. In his work, Dr. Rossi uses data from administrative claims, electronic medical records, medical chart reviews, and patient and physician surveys. His research has covered many different study designs, including comparative effectiveness research, burden of illness, disease treatment and management patterns, causal inference, systematic literature reviews and meta-analyses, and cost-effectiveness analyses. Dr. Rossi’s work has been published in leading peer-reviewed journals and presented at international conferences on health care research.
- 
                                                        Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and JapanJCO Global Oncology, 2024 
 2024Leal TA, Dasgupta A, Latremouille-Viau D, Rossi C, Rai P, Barlesi F, Liu SV 
- 
                                                        PSA Outcomes and Clinical Surveillance Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer Treated With a Next-Generation Androgen Receptor Inhibitor in Urology Practices With or Without In-Office DispensingJournal of Clinical Pathways, 2024 
 2024Burbage SC, Waters D, Rossi C, Kinkead F, Muser E, Ellis L, Lefebvre P, Pilon D 
- 
                                                        Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamideFuture Oncology, 2024 
 2024Lowentritt BH, Du S, Rossi C, Muser E, Khilfeh I, Kinkead F, Korsiak J, Lefebvre P, Pilon D, Agarwal N 
- 
                                                        Treatment patterns for patients with BRCA1/2-positive metastatic castration-resistant prostate cancerThe Oncologist, 2024 
 2024Bilen MA, Khilfeh I, Rossi C, Morrison L, Diaz L, Hilts A, Lefebvre P, Pilon D, George DJ 
- 
                                                        Economic Burden Associated With Nasal Polyposis Recurrence Among Commercially Insured Patients in the United StatesOtolaryngology–Head and Neck Surgery, 2023 
 2023Zhdanava M, Ndife B, Pilon D, Rossi C, Vermette-Laforme M, Lefebvre P, Suh JD 
- 
                                                        Attainment of Early, Deep Prostate-Specific Antigen Response in Metastatic Castration-Sensitive Prostate Cancer: A Comparison of Patients Initiated on Apalutamide or EnzalutamideUrologic Oncology, 2023 
 2023Lowentritt B, Pilon D, Khilfeh I, Rossi C, Muser E, Kinkead F, Waters D, Ellis L, Lefebvre P, Brown G 
- 
                                                        Comparison of Prostate-Specific Antigen Response in Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide or Abiraterone Acetate: A Retrospective Cohort StudyUrologic Oncology, 2023 
 2023Lowentritt B, Pilon D, Waters D, Rossi C, Muser E, Kurteva S, Shah A, Khilfeh I, Du S, Ellis L, Lefebvre P, Brown G 
- 
                                                        Respiratory Syncytial Virus-Related Complications and Healthcare Costs among a Medicare-Insured Population in the United StatesOpen Forum Infectious Diseases, 2023 
 2023DeMartino JK, Lafeuille MH, Emond B, Rossi C, Wang J, Liu S, Lefebvre P, Krishnarajah G 
- 
                                                        Real-World Weight Changes in People with Hiv-1 at Risk of Weight Gain (Female, Black or Hispanic) Switching from Integrase Strand Transfer InhibitorsJournal of Comparative Effectiveness Research, 2023 
 2023Donga P, Emond B, Shah A, Bookhart BK, Anderson D, Vermette-Laforme M, Rossi C, Lafeuille MH 
- 
                                                        Incidence of Cardiometabolic Outcomes among People Living with HIV-1 Initiated on Integrase Strand Transfer Inhibitor Versus Non-Integrase Strand Transfer Inhibitor Antiretroviral Therapies: A Retrospective Analysis of Insurance Claims in the United StatesJournal of International AIDS Society, 2023 
 2023Rebeiro PF, Emond B, Rossi C, Bookhart BK, Shah A, Caron-Lapointe G, Lafeuille MH, Donga P 
- 
                                                        Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1ClinicoEconomics and Outcomes Research, 2023 
 2023Donga P, Emond B, Rossi C, Bookhart BK, Lee J, Caron-Lapointe G, Wei F, Lafeuille MH 
- 
                                                        Early prostate-specific antigen response among Black and non-Black patients with advanced prostate cancer treated with apalutamideFuture Oncology, 2022 
 2022Bivins VM, Durkin M, Khilfeh I, Rossi C, Kinkead F, Waters D, Lefebvre P, Pilon D, Ellis L 
- 
                                                        CML-475 Real-World Treatment Patterns Among Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cycling Through Multiple Tyrosine Kinase Inhibitors (TKIs) in the United States (US)Clinical Lymphoma, Myeloma & Leukemia, 2022 
 2022Kota V, Maegawa R, Latremouille-Viau D, Jadhav K, Rossi C, Guérin A, Lorga S 
- 
                                                        Association Between Weight Gain and the Incidence of Cardiometabolic Conditions Among People Living with HIV-1 at High Risk of Weight Gain Initiated on Antiretroviral TherapyInfectious Diseases and Therapy, 2022 
 2022McComsey GA, Emond B, Shah A, Bookhart BK, Rossi C, Milbers K, Lafeuille MH, Donga P 
- 
                                                        Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial PerspectiveJournal of Health Economics and Outcomes Research, 2022 
 2022Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A 
- 
                                                        Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United StatesJournal of Health Economics and Outcomes Research, 2022 
 2022Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P 
- 
                                                        Economic Burden of Commercially Insured Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United StatesJournal of Clinical Psychiatry, 2022 
 2022Pilon D, Neslusan C, Zhdanava M, Sheehan J, Joshi K, Morrison L, Rossi C, Lefebvre P, Greenberg P 
- 
                                                        Incidence and economic burden of respiratory syncytial virus among adults in the United States: A retrospective analysis using 2 insurance claims databasesJournal of Managed Care & Specialty Pharmacy, 2022 
 2022Mesa-Frias M, Rossi C, Emond B, Bookhart B, Anderson D, Drummond S, Wang J, Lefebvre P, Lamerato LE, Lafeuille MH 
- 
                                                        Real-World Prostate-Specific Antigen Response and Treatment Adherence of Apalutamide in Patients with Non-Metastatic Castration-Resistant Prostate CancerUrology, 2022 
 2022Lowentritt B, Brown G, Pilon D, Ellis L, Germain G, Rossi C, Lefebvre P, Kernen K, Sieber P, Shore N 
- 
                                                        Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United StatesCurrent Medical Research and Opinion, 2022 
 2022Emond B, Rossi C, Côté-Sergent A, Bookhart B, Anderson D, Lefebvre P, Lafeuille MH, Donga P 
- 
                                                        Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United StatesJournal of Health Economics and Outcomes Research, 2022 
 2022Emond B, Rossi C, Rogers R, Lefebvre P, Lafeuille MH, Donga P 
- 
                                                        Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updatesLeukemia & Lymphoma, 2021 
 2021Atallah EL, Sadek I, Maegawa R, Cao X, Latrémouille-Viau D, Pivneva I, Rossi C, Guérin A, Kota V 
- 
                                                        Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorderCurrent Medical Research and Opinion, 2021 
 2021Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C 
- 
                                                        Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant DepressionAdvances in Therapy, 2021 
 2021Zhdanava M, Karkare S, Pilon D, Joshi K, Rossi C, Morrison L, Sheehan J, Lefebvre P, Lopena O, Citrome L 
- 
                                                        Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychoticsJournal of Managed Care & Specialty Pharmacy, 2021 
 2021Pilon D, Patel C, Lafeuille MH, Zhdanava M, Lin D, Côté-Sergent A, Rossi C, Lefebvre P, Joshi K 
- 
                                                        Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiariesCurrent Medical Research and Opinion, 2021 
 2021Pilon D, Patel C, Lafeuille MH, Zhdanava M, Lin D, Côté-Sergent A, Rossi C, Joshi K, Lefebvre P 
- 
                                                        HCV reinfection rates after cure or spontaneous clearance among HIV-infected and uninfected men who have sex with menLiver International, 2021 
 2021Adu PA, Rossi C, Binka M, Wong S, Wilton J, Wong J, Butt ZA, Bartlett S, Jeong D, Pearce M, Darvishian M, Yu A, Alvarez M, García HAV, Krajden M, Janjua NZ 
- 
                                                        Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective StudyJournal of Health Economics and Outcomes Research, 2021 
 2021Emond B, Rossi C, Côté-Sergent A, Dunn K, Lefebvre P, Lafeuille MH, Donga P 
- 
                                                        Prevalence of Potential Drug-Drug Interactions and Pre-existing Conditions for Adverse Events in Augmentation Therapies Among Patients With Treatment-resistant DepressionPsych Congress, 2020 
 2020Zhdanava M, Karkare S, Pilon D, Joshi K, Rossi C, Morrison L, Sheehan J, Lefebvre P, Lopena O, Citrome L 
- 
                                                        An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virusCurrent Medical Research and Opinion, 2020 
 2020Chow W, Donga P, Côté-Sergent A, Rossi C, Lefebvre P, Lafeuille MH, Emond B, Hardy H 
- 
                                                        Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir AlafenamidePatient Preference and Adherence, 2020 
 2020Chow W, Donga P, Côté-Sergent A, Rossi C, Lefebvre P, Lafeuille MH, Hardy H, Emond B 
- 
                                                        Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical ConditionsJournal of Managed Care & Specialty Pharmacy, 2020 
 2020Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C 
- 
                                                    August 5, 2024
- 
                                                    January 29, 2024
- 
                                                    December 1, 2023
- 
                                                    October 23, 2023
- 
                                                    March 2, 2023
- 
                                                    April 12, 2022
- 
                                                    March 29, 2022
- 
                                                    October 15, 2021
- 
                                                    April 13, 2021
- 
                                                    January 21, 2021
 
        